botulinum toxin type A
botulinum toxin type A: developed by 1 company · 54 clinical trials tracked · 1 FDA decision.
botulinum toxin type A evidence translation
What we can confirm
1 FDA record · 54 tracked trials
What it means
What to watch
Prepared research question
How could botulinum toxin type A → RVNC affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Development Pipeline (3)
| Company | Phase |
|---|---|
| Revance Therapeutics, Inc. (RVNC) Benign Essential Blepharospasm; Adductor Spasmodic Dysphonia | Phase 4 |
| Revance Therapeutics, Inc. (RVNC) Glabellar Frown Lines | Phase 4 |
| Revance Therapeutics, Inc. (RVNC) Glabellar Frown Lines | Phase 4 |
Clinical Trials (54)showing 10 most recent
A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD
Primary endpoint: Motor Alignment Success
Effect of Internal Anal Sphincter Botulinum Toxin A Injection 7 Days Before Hemorrhoidectomy on Postoperative Pain: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Primary endpoint: Postoperative Pain Intensity Within the First 7 Days After Hemorrhoidectomy
Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea: a Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study
Primary endpoint: Patient Global Improvement
Investigating the Efficacy of Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis Management
Primary endpoint: Synkinesis Assessment Questionnaire (SAQ)
Hyaluronic Acid Versus Botox Injection in Treatment of Life Long Drug Resistant Premature Ejaculation. Which is Better? Randomized Study
Primary endpoint: Change in intravaginal ejaculatory latency time
PREoperative Targeted OnabotulinumtoXina Injection for Abdominal Wall Reconstruction: A Randomized, Double-Blind, Placebo-Controlled Trial
Primary endpoint: Primary Fascial Closure (PFC) at conclusion of Hernia Surgery (Yes / No, determined by surgeon)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Episodic Migraine
Primary endpoint: Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Chronic Migraine
Primary endpoint: Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial
Primary endpoint: Degree of pain
Medium-and Long-term Efficacy of Two Ultrasound-guided Intra-articular Injections of onabotulinumtoxinA (Botox®) Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis : a Randomized Double-blind Controlled Trial in Three-parallel Arms
Primary endpoint: Base-of-thumb pain on a self-administered 11-point numeric rating scale
FDA Decisions1 records
Frequently asked questions
Who is developing botulinum toxin type A?
botulinum toxin type A is being developed by Revance Therapeutics, Inc..
How many clinical trials involve botulinum toxin type A?
BioSniper tracks 54 clinical trials involving botulinum toxin type A.
What is botulinum toxin type A's latest FDA decision?
The most recent tracked FDA decision for botulinum toxin type A is Approval, dated September 7, 2022.